Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
about
Treatment options in androgen-independent prostate cancer.Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy.Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Circulating steroid hormones in prostate carcinogenesis. Part 1 - Androgens.Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.Expression, structure, and function of androgen receptor in advanced prostatic carcinoma.Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
P2860
Q33539954-D4755A76-A3D8-481E-98A7-6670E7BD2888Q33748701-F001EFD6-E6ED-406E-9EB5-75B98329C77BQ33889276-8A0D5D42-B631-456E-9D37-AF6C62F385E5Q35987124-16C9766A-AEB2-4E66-98C0-C3DBEDE99469Q36619745-23D024DE-1B25-4AF0-B932-996CBBB6D348Q37318328-3C05FC6D-5BFC-4CB0-81DC-8D68E09D74D0Q37829693-B7354789-9BE8-416E-A319-524680FBA100Q38195921-CE2267CE-7FF6-46EC-80FC-D31DF2FACDA8Q38309205-DA2BDAA5-18BF-419B-B14F-88FAC55A8633Q38471454-80F6DE25-B3DF-4831-A746-1A728475C9F5Q39445208-2A58A673-6669-40BB-956A-6B8B00871135Q41736561-9097E240-C5B6-41CC-9C83-7941CA2CC9FCQ43077983-EAF2742E-1CDF-4D89-BEBC-FB805A27E690Q46004084-9CFD7403-0743-41DA-9263-D12031425EF5Q53176477-7AEC6924-1A55-4065-882F-518B575BA7B6
P2860
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
description
1994 nî lūn-bûn
@nan
1994 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Surprising activity of flutami ...... e-refractory" prostate cancer.
@ast
Surprising activity of flutami ...... e-refractory" prostate cancer.
@en
type
label
Surprising activity of flutami ...... e-refractory" prostate cancer.
@ast
Surprising activity of flutami ...... e-refractory" prostate cancer.
@en
prefLabel
Surprising activity of flutami ...... e-refractory" prostate cancer.
@ast
Surprising activity of flutami ...... e-refractory" prostate cancer.
@en
P2093
P356
P1476
Surprising activity of flutami ...... e-refractory" prostate cancer.
@en
P2093
Linehan WM
Steinberg S
Thibault A
Tompkins A
Weinberger M
P304
P356
10.1093/JNCI/86.3.222
P407
P577
1994-02-01T00:00:00Z